Abstract library

16 results for "Sasano".
#38 Expression of mTOR signaling pathway and effects of mTOR inhibitors on its pathway in human neuroendocrine tumors
Introduction: Neuroendocrine tumors (NET), especially well-differentiated endocrine tumors, are often slow-growing, indolent, and may not become clinically apparent until the manifestations of metastatic spread or carcinoid syndrome. Results of previous studies demonstrated that phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway may be activated in the great majority of NET cells. mTOR inhibitors are therefore considered effective anti-tumor reagents but they may also induce an activation of PI3K/Akt and MAPK pathways as a compensatory action and reduce their own anti-tumor activities.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Professor Hironobu Sasano
Authors: Iida S, Miki Y, Ono K, Sasano H
#96 Expression of components of the mTOR pathway in gastroenteropancreatic neuroendocrine tumors
Introduction: Recently, the mammalian target of rapamycin (mTOR) inhibitors have entered late phase clinical trials in a broad variety of solid human malignancies, including neuroendocrine tumors (NETs). Since these drugs will certainly be used as routine therapeutics in the near future, it is surprising that information on the exact expression patterns of mTOR and its downstream target 4EBP1 in NETs is still lacking.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Atsuko Kasajima
#226 Insulin-like Growth Factor-1 Receptor (IGF-1R) and its Inhibition in Non-functioning Neuroendocrine Tumors
Introduction: Insulin-like growth factor-1 receptor (IGF-1R) was reported to be expressed in NET (neuroendocrine tumor) cells but its biological roles and activation status in non-functioning NET are unknown.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Professor Hironobu Sasano
Authors: Sasano H, Iida S, Ono K, Nakamura Y, ...
#729 Neuroendocrine Neoplasms of the Ampulla of Vater: Clinicopathological Analysis of Nine Cases
Introduction: Neuroendocrine neoplasms (NEN) of the ampulla of Vater (AV) are rare and heterogeneous and little is known about their biological behavior.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Luis Perez-Casanova
#971 Well-differentiated Pancreatic Neuroendocrine Tumors: Prognostic Significance of Pathological Parameters
Introduction: Well-differentiated (WD) pancreatic neuroendocrine tumors (pNET) are uncommon neoplasms and one challenge lies in predicting tumor behavior and managing these patients.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Luis Pérez-Casanova
#1176 Clinical and Pathologic Characteristics of Small Cell Neuroendocrine Carcinoma of the Bladder
Introduction: Small cell carcinoma of the bladder (SCC) is a poorly differentiated neuroendocrine (NE) neoplasm accounting less than 1% of all bladder tumors, 1/3 are admixed with conventional urothelial carcinoma and hematuria is the most common clinical presentation. The unknown etiology and natural history of SCC represent a challenge for its diagnosis and treatment.
Conference: 12th Annual ENETS Conference (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Luis Perez-Casanova
#1286 A Comparative Analysis of Ki67 Index of the High Grade Neuroendocrine Neoplasms Arising in the Gastrointestinal Tract and the Pancreas
Introduction: A common classification has been used for NET in gastrointestinal tract (GI-NET) and pancreas (P-NET), but heterogeneity has been reported in high grade tumors; well-differentiated G3 (WDG3), poorly differentiated NEC (NEC), and mixed adenoneuroendocrine carcinoma (MANEC).
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
#1382 Appropriate Indication of Organ Preserving Surgery for Pancreatic Neuroendocrine Neoplasm
Introduction: Organ preserving surgery(OPS) has been accepted for pancreatic neuroendocrine neoplasm(PNEN), particularly in a small and low malignant tumors.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Dr Takahiro Tsuchikawa
#1657 Establishment of Japan NeuroEndocrine Tumor Society and Its Registration System
Introduction: In 2012, many nation-wide gastroenterologists, endocrinologists, surgeons, radiologists and pathologists have established Japan NeuroEndocrine Tumor Society (JNETS) in Japan. JNETS is now composed of 304 institutes.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: M.D., Ph.D. Toshihiko Masui
Authors: Masui T, Imamura M, Ito T, Unno M, ...
#1666 Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on “NET G3”: An Analysis of 198 Cases from Japan
Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Keywords: NET G3, GEP-NEN, GI-NET